[go: up one dir, main page]

TW200916458A - Heterocyclic compounds and methods of use thereof - Google Patents

Heterocyclic compounds and methods of use thereof Download PDF

Info

Publication number
TW200916458A
TW200916458A TW097133986A TW97133986A TW200916458A TW 200916458 A TW200916458 A TW 200916458A TW 097133986 A TW097133986 A TW 097133986A TW 97133986 A TW97133986 A TW 97133986A TW 200916458 A TW200916458 A TW 200916458A
Authority
TW
Taiwan
Prior art keywords
group
alkyl
compound
ring
doc
Prior art date
Application number
TW097133986A
Other languages
English (en)
Chinese (zh)
Inventor
Benjamin Fauber
Alexander Hird
James Janetka
Daniel John Russell
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200916458A publication Critical patent/TW200916458A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW097133986A 2007-09-05 2008-09-04 Heterocyclic compounds and methods of use thereof TW200916458A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97010707P 2007-09-05 2007-09-05
US3666108P 2008-03-14 2008-03-14

Publications (1)

Publication Number Publication Date
TW200916458A true TW200916458A (en) 2009-04-16

Family

ID=39938463

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097133986A TW200916458A (en) 2007-09-05 2008-09-04 Heterocyclic compounds and methods of use thereof

Country Status (5)

Country Link
AR (1) AR068376A1 (es)
PE (1) PE20091092A1 (es)
TW (1) TW200916458A (es)
UY (1) UY31322A1 (es)
WO (1) WO2009030952A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014012511A1 (en) * 2012-07-19 2014-01-23 Impact Therapeutics, Inc. N-(3-heteroarylaryl)-4-arylarylcarboxamtdes and analogs as hedgehog pathway inhibitors and use thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2440048B8 (en) 2009-06-09 2015-12-16 NantBioScience, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
JP2013516480A (ja) * 2010-01-07 2013-05-13 セレクサゲン セラピューティクス，インク． ヘッジホッグ阻害剤
WO2011095807A1 (en) * 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
CN101993415B (zh) * 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CA3037456A1 (en) 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
US20190255042A1 (en) * 2016-11-04 2019-08-22 Impact Therapeutics, Inc Application of hedgehog pathway inhibitor in treating fibrosis diseases
IL270224B1 (en) 2017-05-02 2024-04-01 Novartis Ag Combination therapy employing trametinib and a defined raf inhibitor
CN107281214A (zh) * 2017-06-06 2017-10-24 北京工业大学 氢分子液体/气体在制备抑制肿瘤干细胞药物中的应用
CN109369634B (zh) * 2018-12-19 2021-07-27 陕西国际商贸学院 具有抗肿瘤活性的2-甲氧基烟酰胺衍生物制备方法及用途
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
US12018015B2 (en) 2021-06-18 2024-06-25 Aligos Therapeutics, Inc. Methods and compositions for targeting PD-L1
WO2023114365A1 (en) 2021-12-16 2023-06-22 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101058292B1 (ko) * 2002-02-12 2011-08-22 글락소스미스클라인 엘엘씨 Ｐ38 억제제로 유용한 니코틴아미드 유도체
ATE404200T1 (de) * 2002-04-22 2008-08-15 Univ Johns Hopkins Med Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
WO2006078283A2 (en) * 2004-04-30 2006-07-27 Genentech, Inc. Quinoxaline inhibitors of hedgehog signalling
KR20160058972A (ko) * 2004-09-02 2016-05-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
CA2587489C (en) * 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2620899A1 (en) * 2005-10-12 2007-04-19 Biolipox Ab Benzoxazoles useful in the treatment of inflammation
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014012511A1 (en) * 2012-07-19 2014-01-23 Impact Therapeutics, Inc. N-(3-heteroarylaryl)-4-arylarylcarboxamtdes and analogs as hedgehog pathway inhibitors and use thereof
US10676468B2 (en) 2012-07-19 2020-06-09 Impact Therapeutics, Inc. N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof

Also Published As

Publication number Publication date
WO2009030952A2 (en) 2009-03-12
AR068376A1 (es) 2009-11-11
WO2009030952A3 (en) 2009-05-07
PE20091092A1 (es) 2009-08-27
UY31322A1 (es) 2009-04-30

Similar Documents

Publication Publication Date Title
TW200916458A (en) Heterocyclic compounds and methods of use thereof
TWI433677B (zh) 雜環化合物及其用途
JP6736559B2 (ja) トリアゾロピリミジン化合物およびその使用
KR101530117B1 (ko) 야누스 키나제 억제제 화합물 및 방법
TW200918521A (en) Heterocyclic amides and methods of use thereof
KR20230170039A (ko) Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
US10676438B2 (en) KCNQ2-5 channel activator
WO2012000304A1 (zh) 杂环炔苯类化合物及其药用组合物和应用
JP2022530097A (ja) がんを処置するためのアシルスルホンアミド類
CN107531683B (zh) Usp7抑制剂化合物及使用方法
CN105793260A (zh) 作为用于治疗癌症的raf抑制剂的1-(5-叔丁基-2-芳基-吡唑-3-基)-3-[2-氟-4-[(3-氧代-4h-吡啶并[2，3-b]吡嗪-8-基)氧基]苯基]脲衍生物
TW201008929A (en) Organic compounds as Smo inhibitors
CN106883213A (zh) 一种新型egfr和alk激酶的双重抑制剂
TW200906825A (en) Inhibitors of protein kinases
CN102712635A (zh) 用于抑制raf激酶的1h-吡唑并[3,4-b]吡啶化合物
JP2014520860A (ja) タンキラーゼ阻害剤として使用するための４−オキソ−３，５，７，８−テトラヒドロ−４Ｈ−ピラノ｛４，３−ｄ｝ピルミニジニル化合物
JP6257835B2 (ja) 新規なトリアゾロピリミジノン又はトリアゾロピリジノン誘導体、及びこれらの用途
WO2014082578A1 (zh) 杂芳基炔烃化合物及其应用
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
CN110437220B (zh) 三氮唑类化合物及其应用
CN102020648B (zh) 3-芳基-6-芳基-[1,2,4]三唑并[4,3-b]哒嗪作为细胞增殖抑制剂及其应用
CN110386901B (zh) 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用
TWI546304B (zh) Protein tyrosine kinase inhibitors and their use
KR102046196B1 (ko) 이미다조피리딘 유도체의 치료적 용도
CN114555597A (zh) 异柠檬酸脱氢酶（idh）抑制剂